Cargando…

Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology

INTRODUCTION: Xuanhuang Pill (XHP) is a traditional Chinese medicine oral formula composed of 10 herbs. This study aims to verify the hepatoprotective activity of XHP and explain its possible mechanism. METHODS: The hepatoprotective activity of XHP was evaluated by constructing a mouse model of alco...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Xuejie, Du, Maobo, Wei, Kunhua, Dai, Chen, Yang, Rachel Y. H., Zhou, Bingxue, Luo, Zhaojing, Yang, Xiaonan, Yu, Yi, Lin, Wei, Wu, Yi, Liu, Yuhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111029/
https://www.ncbi.nlm.nih.gov/pubmed/37082132
http://dx.doi.org/10.3389/fendo.2023.1175985
_version_ 1785027376352067584
author Cui, Xuejie
Du, Maobo
Wei, Kunhua
Dai, Chen
Yang, Rachel Y. H.
Zhou, Bingxue
Luo, Zhaojing
Yang, Xiaonan
Yu, Yi
Lin, Wei
Wu, Yi
Liu, Yuhong
author_facet Cui, Xuejie
Du, Maobo
Wei, Kunhua
Dai, Chen
Yang, Rachel Y. H.
Zhou, Bingxue
Luo, Zhaojing
Yang, Xiaonan
Yu, Yi
Lin, Wei
Wu, Yi
Liu, Yuhong
author_sort Cui, Xuejie
collection PubMed
description INTRODUCTION: Xuanhuang Pill (XHP) is a traditional Chinese medicine oral formula composed of 10 herbs. This study aims to verify the hepatoprotective activity of XHP and explain its possible mechanism. METHODS: The hepatoprotective activity of XHP was evaluated by constructing a mouse model of alcoholic liver disease, and the mechanism of XHP was preliminarily explained by utilizing ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC-QTOF/MS), proteomics and network pharmacology. RESULTS: The current study demonstrated that treatment with XHP ameliorated acute alcohol-induced liver injury in mice by significantly reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and triglycerides (TGs) and malondialdehyde (MDA) content. Remarkably, treatment also increased superoxide dismutase (SOD) activity and glutathione (GSH) content. UPLC-QTOF/MS, 199 compounds were identified as within the make-up of the XHP. Network pharmacology analysis showed that 103 targets regulated by 163 chemical components may play an important role in the protective liver effect mediated by XHP. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis suggest that the HIF-1, FoxO, PI3K-Akt, insulin, and thyroid hormone signaling pathways are key modulators of XHP’s effects. Finally, eight key targets including Mapk1, Mapk3, Akt1, Map2k1, Pik3ca, Pik3cg, Raf1, and Prkca were verified by molecular docking and proteomics analysis, which provide insight into the hepatoprotective effect observed with XHP treatment. CONCLUSION: In summary, these results improved upon knowledge of the chemical composition and the potential mechanisms of hepatoprotective action of oral XHP treatment, providing foundational support for this formulation as a viable therapeutic option for alcoholic liver disease.
format Online
Article
Text
id pubmed-10111029
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101110292023-04-19 Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology Cui, Xuejie Du, Maobo Wei, Kunhua Dai, Chen Yang, Rachel Y. H. Zhou, Bingxue Luo, Zhaojing Yang, Xiaonan Yu, Yi Lin, Wei Wu, Yi Liu, Yuhong Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Xuanhuang Pill (XHP) is a traditional Chinese medicine oral formula composed of 10 herbs. This study aims to verify the hepatoprotective activity of XHP and explain its possible mechanism. METHODS: The hepatoprotective activity of XHP was evaluated by constructing a mouse model of alcoholic liver disease, and the mechanism of XHP was preliminarily explained by utilizing ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC-QTOF/MS), proteomics and network pharmacology. RESULTS: The current study demonstrated that treatment with XHP ameliorated acute alcohol-induced liver injury in mice by significantly reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and triglycerides (TGs) and malondialdehyde (MDA) content. Remarkably, treatment also increased superoxide dismutase (SOD) activity and glutathione (GSH) content. UPLC-QTOF/MS, 199 compounds were identified as within the make-up of the XHP. Network pharmacology analysis showed that 103 targets regulated by 163 chemical components may play an important role in the protective liver effect mediated by XHP. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis suggest that the HIF-1, FoxO, PI3K-Akt, insulin, and thyroid hormone signaling pathways are key modulators of XHP’s effects. Finally, eight key targets including Mapk1, Mapk3, Akt1, Map2k1, Pik3ca, Pik3cg, Raf1, and Prkca were verified by molecular docking and proteomics analysis, which provide insight into the hepatoprotective effect observed with XHP treatment. CONCLUSION: In summary, these results improved upon knowledge of the chemical composition and the potential mechanisms of hepatoprotective action of oral XHP treatment, providing foundational support for this formulation as a viable therapeutic option for alcoholic liver disease. Frontiers Media S.A. 2023-04-04 /pmc/articles/PMC10111029/ /pubmed/37082132 http://dx.doi.org/10.3389/fendo.2023.1175985 Text en Copyright © 2023 Cui, Du, Wei, Dai, Yang, Zhou, Luo, Yang, Yu, Lin, Wu and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Cui, Xuejie
Du, Maobo
Wei, Kunhua
Dai, Chen
Yang, Rachel Y. H.
Zhou, Bingxue
Luo, Zhaojing
Yang, Xiaonan
Yu, Yi
Lin, Wei
Wu, Yi
Liu, Yuhong
Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title_full Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title_fullStr Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title_full_unstemmed Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title_short Study of Xuanhuang Pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
title_sort study of xuanhuang pill in protecting against alcohol liver disease using ultra-performance liquid chromatography/time-of-flight mass spectrometry and network pharmacology
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111029/
https://www.ncbi.nlm.nih.gov/pubmed/37082132
http://dx.doi.org/10.3389/fendo.2023.1175985
work_keys_str_mv AT cuixuejie studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT dumaobo studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT weikunhua studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT daichen studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT yangrachelyh studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT zhoubingxue studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT luozhaojing studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT yangxiaonan studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT yuyi studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT linwei studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT wuyi studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology
AT liuyuhong studyofxuanhuangpillinprotectingagainstalcoholliverdiseaseusingultraperformanceliquidchromatographytimeofflightmassspectrometryandnetworkpharmacology